Tremelimumab plus Durvalumab Prior to Chemoradiotherapy in Unresectable Locally Advanced NSCLC, the Induction Trial

被引：0
|
作者：
Smeenk, M. M. [1 ]
van Diessen, J. N. A. [1 ]
Boellaard, T. N. [1 ]
Hartemink, K. J. [1 ]
de Vries, J. F. [1 ]
Badrising, S. K. [1 ]
Wondergem, M. [1 ]
Wittenberg, R. [1 ]
Monkhorst, K. [1 ]
van den Heuvel, M. M. [2 ]
Theelen, W. S. M. E. [1 ]
机构：
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
Induction; Immunotherapy; Locally advanced NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA16.03
引用
收藏
页码：S157 / S157
页数：1
相关论文
共 50 条
  • [41] Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
    Hiraoka, Atsushi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ohama, Hideko
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kosaka, Hisashi
    Matono, Tomomitsu
    Kuroda, Hidekatsu
    Yata, Yutaka
    Nishikawa, Hiroki
    Imai, Michitaka
    Aoki, Tomoko
    Ochi, Hironori
    Tada, Fujimasa
    Nakamura, Shinichiro
    Nakamura, Yoshiko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Tsutsui, Akemi
    Nagano, Takuya
    Tanaka, Kazunari
    Tanaka, Hironori
    Koshiyama, Yuichi
    Kanayama, Yuki
    Noritake, Hidenao
    Enomoto, Hirayuki
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    Kumada, Takashi
    HEPATOLOGY RESEARCH, 2025, 55 (03) : 444 - 453
  • [42] A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer
    Lee, Ji Yun
    Sun, Jong-Mu
    Oh, Dongryul
    Lim, Sung Hee
    Chi, Sangah
    Lee, Se-Hoon
    Jung, Sin-Ho
    Ahn, Myung-Ju
    Ahn, Yong Chan
    Park, Keunchil
    RADIOTHERAPY AND ONCOLOGY, 2017, 122 (02) : 217 - 223
  • [43] Definitive chemoradiotherapy with Carboplatin Plus Paclitaxel for Unresectable Locally Advanced Thymic Carcinoma: A case series
    Nozaki, Koichiro
    Watanabe, Satoshi
    Yamazaki, Ryo
    Arita, Masashi
    Kikuchi, Toshiaki
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2024, 16
  • [44] Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial"
    Yu, Shaorong
    Feng, Jifeng
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (01) : 173 - 174
  • [45] Safety and efficacy of durvalumab (MEDI4736) plus tremelimumab in advanced non-small-cell lung cancer (NSCLC)
    Karakunnel, Joyson J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma
    Wang, Qiaoli
    Xu, Guoqiang
    Xia, Yaoxiong
    Zuo, Jia
    Zeng, Guilin
    Xue, Zhihong
    Cao, Ruixue
    Xiong, Wei
    Li, Wenhui
    ORAL ONCOLOGY, 2020, 111
  • [47] Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
    Capdevila, J.
    Hernando, J.
    Teule, A.
    Lopez, C.
    Garcia-Carbonero, R.
    Benavent, M.
    Custodio, A.
    Garcia-Alvarez, A.
    Cubillo, A.
    Alonso, V.
    Carmona-Bayonas, A.
    Alonso-Gordoa, T.
    Crespo, G.
    Jimenez-Fonseca, P.
    Blanco, M.
    Viudez, A.
    La Casta, A.
    Sevilla, I.
    Segura, A.
    Llanos, M.
    Landolfi, S.
    Nuciforo, P.
    Manzano, J. L.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [48] Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
    J. Capdevila
    J. Hernando
    A. Teule
    C. Lopez
    R. Garcia-Carbonero
    M. Benavent
    A. Custodio
    A. Garcia-Alvarez
    A. Cubillo
    V. Alonso
    A. Carmona-Bayonas
    T. Alonso-Gordoa
    G. Crespo
    P. Jimenez-Fonseca
    M. Blanco
    A. Viudez
    A. La Casta
    I. Sevilla
    A. Segura
    M. Llanos
    S. Landolfi
    P. Nuciforo
    J. L. Manzano
    Nature Communications, 14
  • [49] Durvalumab plus tremelimumab for advanced hepatocellular carcinoma is associated with a neutrophil/lymphocyte ratio
    Sugimoto, Rie
    Senjyuu, Takeshi
    Aratake, Yoshifusa
    Kuwano, Akifumi
    Ueda, Akihiro
    Nakamura, Tsukasa
    Goya, Takeshi
    Morita, Yuusuke
    Tanaka, Yuki
    Kojima, Motoyuki
    Tanaka, Masatake
    CANCER SCIENCE, 2025, 116 : 963 - 963
  • [50] Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma
    Xu, Guoqiang
    Wang, Qiaoli
    Wu, Xingrao
    Lv, Chunyan
    Zeng, Guilin
    Xue, Zhihong
    Cao, Ruixue
    Zhang, Nan
    Xiong, Wei
    Huang, Qin
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2021, 20
12345